Myeloproliferative Disorders

17 treatments and conditions followed through the public trial records. Not medical advice. How a status is set

Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.

Broader: Hematologic Diseases

Narrower: Primary Myelofibrosis 10, Thrombocythemia, Essential 3

Treatments and conditions

Myeloproliferative Disorders
Treatment and conditionWhere it standsTrials
Azacitidine + Ascorbic Acid for myeloproliferative disordersPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Bezuclastinib for myeloproliferative disordersPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Givinostat for primary myelofibrosisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Givinostat for thrombocythemia, essentialTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + CYTARABINE + ASPARAGINASE ERWINIA CHRYSANTHEMI + ASPARAGINASE + Mitoxantrone Hydrochloride for myeloproliferative disordersPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + CYTARABINE + ETOPOSIDE + THIOGUANINE + Daunorubicin Hydrochloride for myeloproliferative disordersPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Luspatercept for primary myelofibrosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Navitoclax for primary myelofibrosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Peginterferon α-2b injection for thrombocythemia, essentialPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pelabresib for primary myelofibrosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Peripheral Blood Hematopoietic Cell Transplantation (HCT) + Total body irradiation (TBI) + Cyclophosphamide + Busulfan + FLUDARABINE + FILGRASTIM + Mycophenolate Mofetil Hydrochloride + Sirolimus for primary myelofibrosisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
ROPEGINTERFERON ALFA-2B for thrombocythemia, essentialPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ruxolitinib + NAVITOCLAX for primary myelofibrosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Selinexor for primary myelofibrosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tasquinimod for primary myelofibrosisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
TASQUINIMOD + Ruxolitinib for primary myelofibrosisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
ULIXERTINIB + Ruxolitinib for primary myelofibrosisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1

Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.